Chronic inflammation/autoimmune diseases

We have been among the pioneers in understanding the autoimmune background of type 1 diabetes. Based on this background in immunology and biologics, we seek to supplement our promising pipeline in the inflammation field. Thus, we seek partners with novel and innovative protein therapies for:

  • chronic inflammation and autoimmune diseases.
We welcome opportunities at early discovery phase as well as clinical projects. We do not exclude any, relevant targets, but we particularly focus on validated targets within the following categories:
  • Cell-surface molecules on T cells and NK cells
  • Cytokines and chemokines.


Our position

We have, together with our partners, created an exciting pipeline that is advancing fast towards the clinic, consisting of anti-IL-20, anti-C5aR, and others. We have established a world-wide network of expert advisors within psoriasis, rheumatoid arthritis, systemic lupus, inflammatory bowel disease, and multiple sclerosis.

Our extensive background in diabetes and biologics prompted us to explore new therapeutic areas, and with our strong immunological knowledge within T cells and cytokines, chronic inflammation and autoimmune diseases were logical choices.

Biopharmaceuticals Research Unit

Contact

For further information please contact Biopharmaceuticals Sourcing

Download

Please download the Novo Nordisk:
Partnering folder
Inflammation folder
Nature licensing profile

  •  
  •